أستونيا - الإستونية - Ravimiamet

novartis baltics sia - everoliimus - tablett - 0,25mg 50tk; 0,25mg 60tk; 0,25mg 250tk

أستونيا - الإستونية - Ravimiamet

novartis baltics sia - everoliimus - dispergeeruv tablett - 0,1mg 100tk; 0,1mg 60tk

أستونيا - الإستونية - Ravimiamet

novartis baltics sia - everoliimus - tablett - 0,5mg 50tk; 0,5mg 100tk; 0,5mg 250tk; 0,5mg 60tk

أستونيا - الإستونية - Ravimiamet

novartis baltics sia - everoliimus - dispergeeruv tablett - 0,25mg 100tk; 0,25mg 60tk; 0,25mg 50tk; 0,25mg 250tk

أستونيا - الإستونية - Ravimiamet

fresenius kabi oncology plc - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 100mg 1tk; 5mg 1ml 50mg 1tk

أستونيا - الإستونية - Ravimiamet

gp-pharm s.a. - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 50mg 1tk; 5mg 1ml 100mg 1tk

أستونيا - الإستونية - Ravimiamet

actavis group hf - oksaliplatiin - infusioonilahuse pulber - 5mg 1ml 50mg 1tk; 5mg 1ml 100mg 1tk

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomüoom - hüpofüüsi ja hüpotaalamuse hormoonid ja analoogid - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

الاتحاد الأوروبي - الإستونية - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatiid - osteoporosis; osteoporosis, postmenopausal - kaltsiumi homöostaas - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.